Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Organogenesis Holdings Inc (NASDAQ: ORGO) closed the day trading at $5.39 down -3.58% from the previous closing price of $5.59. In other words, the price has decreased by -$3.58 from its previous closing price. On the day, 2.0 million shares were traded. ORGO stock price reached its highest trading level at $5.65 during the session, while it also had its lowest trading level at $5.242.
Ratios:
For a better understanding of ORGO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.88 and its Current Ratio is at 3.32. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 24 ’25 when Glenn Nussdorf bought 100,000 shares for $5.34 per share.
NUSSDORF GLENN H bought 251,001 shares of ORGO for $775,041 on May 14 ’25. The Director now owns 251,001 shares after completing the transaction at $3.09 per share. On May 15 ’25, another insider, NUSSDORF GLENN H, who serves as the Director of the company, bought 107,494 shares for $2.99 each. As a result, the insider paid 320,999 and bolstered with 358,495 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 684056448 and an Enterprise Value of 791972416. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.47 while its Price-to-Book (P/B) ratio in mrq is 2.68. Its current Enterprise Value per Revenue stands at 1.702 whereas that against EBITDA is 40.498.
Stock Price History:
The Beta on a monthly basis for ORGO is 1.35, which has changed by 0.4116162 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, ORGO has reached a high of $7.08, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is 16.43%, while the 200-Day Moving Average is calculated to be 24.29%.
Shares Statistics:
Over the past 3-months, ORGO traded about 1.48M shares per day on average, while over the past 10 days, ORGO traded about 1944260 shares per day. A total of 126.91M shares are outstanding, with a floating share count of 59.79M. Insiders hold about 52.89% of the company’s shares, while institutions hold 54.12% stake in the company. Shares short for ORGO as of 1761868800 were 10649719 with a Short Ratio of 7.22, compared to 1759190400 on 10767297. Therefore, it implies a Short% of Shares Outstanding of 10649719 and a Short% of Float of 24.39.
Earnings Estimates
Organogenesis Holdings Inc (ORGO) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.09, with high estimates of -$0.09 and low estimates of -$0.09.
Analysts are recommending an EPS of between $0.22 and $0.22 for the fiscal current year, implying an average EPS of $0.22. EPS for the following year is $0.17, with 1.0 analysts recommending between $0.17 and $0.17.
Revenue Estimates
2 analysts predict $172.65M in revenue for. The current quarter. It ranges from a high estimate of $173.3M to a low estimate of $172M. As of. The current estimate, Organogenesis Holdings Inc’s year-ago sales were $126.66MFor the next quarter, 2 analysts are estimating revenue of $99.7M. There is a high estimate of $103.7M for the next quarter, whereas the lowest estimate is $95.7M.
A total of 2 analysts have provided revenue estimates for ORGO’s current fiscal year. The highest revenue estimate was $511.9M, while the lowest revenue estimate was $510.2M, resulting in an average revenue estimate of $511.05M. In the same quarter a year ago, actual revenue was $482.04MBased on 2 analysts’ estimates, the company’s revenue will be $543.4M in the next fiscal year. The high estimate is $551.1M and the low estimate is $535.7M.
